TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2598979
Drug: Glucagon with
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon with surfactants (9-lauryl ether as spray, sodium glycocholate as spray or powder)
Study: 2598979
Drug: Human calcitonin
Normalized name: human calcitonin
DrugBank: Human calcitonin (DB06773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human calcitonin with surfactants (dihydrofusinate as spray or powder, glycocholate as spray)
Study: 2598979
Drug: Powders and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powders and spray solutions of glucagon and calcitonin
Study: 7013055
Drug: sulindac 100
Normalized name: sulindac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulindac 100 mg b.i.d. (plus indomethacin placebo)
Study: 7013055
Drug: indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin 25 mg t.i.d. (plus sulindac placebo)
Study: 26871805
Drug: Intravenous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous low-dose ketamine 0.5 mg/kg (group K)
Study: 20204984
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus psychological preparation
Study: 17586452
Drug: Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimoniate (20mgSb(5)/kg body weight daily for 14 days)
Study: 15637501
Drug: Ginger (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (various forms, dosage not specified)
Study: 9790462
Drug: Dilatation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilatation plus Nd‐YAG laser therapy
Study: 9363233
Drug: Vaginal capsules
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal capsules containing seminal plasma
Study: 30955461
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of delirium
Study: 21325466
Drug: Drospirenone/ethinyl estradiol
Normalized name: DROSPIRENONE/ETHINYL ESTRADIOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone/ethinyl estradiol (3 mg/30 μg)
Study: 19802544
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate capsule
Study: 16763247
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin (3 times daily for 5 days)
Study: 16763247
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 times daily for 5 days)
Study: 15642961
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of Artemotil (4.8 mg/kg on day 0 at 0 hours, 1.6 mg/kg at 6 hours, and 1.6 mg/kg/day on days 1-4)
Study: 15642961
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of Artemotil (3.2 mg/kg on day 0 and 1.6 mg/kg/day on days 1-4)
Study: 15642961
Drug: Patient 151
Normalized name: etranacogene dezaparvovec
DrugBank: Etranacogene dezaparvovec (DB16791)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient 151 (high dose regimen)
Study: 31657712
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg furosemide
Study: 25840035
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus daily tailored text messages for 6 months
Study: 23359039
Drug: Dual-hormone closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-hormone closed-loop delivery
Study: 23359039
Drug: Standard insulin-pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin-pump therapy (control)
Study: 18056753
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy intervention (comparison group)
Study: 14668186
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) in a 0.04 mol/l solution in Plegisol
Study: 8648016
Drug: Albuterol sulfate
Normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol sulfate (4 mg twice daily)
Study: 6643332
Drug: Amikacin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin 7.5 mg/kg by iv infusion
Study: 6643332
Drug: Gentamicin 1.5
Normalized name: HYDROCORTISONE ACEPONATE 1.11 mg in 1 mL / MICONAZOLE NITRATE 17.4 mg in 1 mL / GENTAMICIN 1.5 mg in 1 mL AURICULAR (OTIC) SUSPENSION [EASOTIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 1.5 mg/kg
Study: 6643332
Drug: Tobramycin 1
Normalized name: tobramycin 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 1 mg/kg
Study: 31697304
Drug: Bevacizumab 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 0.625 mg
Study: 31697304
Drug: Bevacizumab 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 0.25 mg, 0.125 mg, 0.063 mg, or 0.031 mg
Study: 28118231
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg (control group)
Study: 28118231
Drug: Dexamethasone 15
Normalized name: MENTHOL 200 mg in 20000 mg / CAMPHOR (SYNTHETIC) 200 mg in 20000 mg / DEXAMETHASONE 15 mg in 20000 mg TOPICAL OINTMENT [999 ITCH RELIEF]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 15 mg (study group)
Study: 28118231
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (5 mg and 15 mg)
Study: 24290111
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol (vitamin D3) 5000 IU/d for 28 days
Study: 15452302
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (1250 mg)
Study: 8315423
Drug: Doxorubicin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (500 mg/m2)
Study: 8315423
Drug: Mitoxantrone (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (120 mg/m2)
Study: 3575355
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylpropanolamine (PPA) 37.5 mg
Study: 18840372
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of 30 mg sublingual ketorolac
Study: 18840372
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of 30 mg sublingual ketorolac
Study: 10563527
Drug: Natural interferon-alphaN3
Normalized name: interferon beta natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural interferon-alphaN3 with N-acetyl cysteine 1200 mg/day and vitamin E 600 mg/day
Study: 27382136
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of television segments and vinyl banners
Study: 23230666
Drug: Micro-invasive surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-invasive surgical therapy (endoscope-assisted posterior operation)
Study: 23230666
Drug: Traditional surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional surgical therapy (control group)
Study: 18758677
Drug: Acupuncture together
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acupuncture together with tricyclic antidepressants and exercise (n=34)
Study: 18758677
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants and exercise only (n=24)
Study: 6723694
Drug: Slow-release mexiletine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release mexiletine 360 mg 12 hourly
Study: 6723694
Drug: Conventional mexiletine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional mexiletine 200 mg 8 hourly
Study: 30672623
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg fixed interval (FI)
Study: 30672623
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg fixed interval (FI)
Study: 29857882
Drug: Herbal acupoint
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal acupoint therapy (HAT)
Study: 20195673
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g/12 h) plus amikacin (15 mg/kg/day)
Study: 20195673
Drug: Piperacillin/tazobactam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (4 g/500 mg/8 h) plus amikacin
Study: 15662091
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg/d)
Study: 11883790
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion (30 g/300 ml/30 min)
Study: 2287792
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 16 mg orally
Study: 2287792
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 4 mg intranasally for 1 week
Study: 2287792
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 1 mg or 16 mg
Study: 27261986
Drug: Focused meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused meditation (8-week program with weekly 75 min classes)
Study: 20586923
Drug: Abciximab bolus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab bolus followed by a 12-h placebo infusion and concomitant 600-mg clopidogrel
Study: 20586923
Drug: Abciximab bolus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab bolus + a 12-h infusion and 300 mg of clopidogrel
Study: 15726575
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTXA) injection with low-frequency electrical nerve stimulation (NS) at 4 Hz
Study: 15726575
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTXA) injection with high-frequency electrical nerve stimulation (NS) at 25 Hz
Study: 15726575
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTXA) injection without electrical nerve stimulation (NS)
Study: 11927114
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of Yuzpe regimen
Study: 11927114
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose of Yuzpe regimen
Study: 11927114
Drug: Yuzpe regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yuzpe regimen (both doses)
Study: 9862249
Drug: Hydrocortisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (50 mg intravenous bolus)
Study: 2651178
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release salbutamol tablets (8 mg twice daily)
Study: 2651178
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release theophylline preparation (400-800 mg given once each night)
Study: 154872
Drug: oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral antibiotic + topical placebo lotion
Study: 154872
Drug: oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral antibiotic + topical ethyl lactate lotion
Study: 154872
Drug: topical ethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical ethyl lactate lotion only
Study: 7488359
Drug: Colgate Winterfresh
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate Winterfresh Gel with 0.76% sodium monofluorophosphate (MFP)
Study: 3328680
Drug: No calcium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No calcium channel blocker (Group 3, n = 15)
Study: 29525970
Drug: Stopping oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping oral bisphosphonate treatment (ibandronate, alendronate, risedronate)
Study: 26073181
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg, dosed twice daily)
Study: 26073181
Drug: Mirogabalin (17.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirogabalin (17.7 mg estimated dose)
Study: 26073181
Drug: Mirogabalin (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirogabalin (twice-daily dosing)
Study: 20622383
Drug: 1 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/day of Fungisome
Study: 20622383
Drug: 3 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg/day of Fungisome
Study: 17078006
Drug: Combination probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination probiotics and nutrients
Study: 11369844
Drug: Early intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intervention with epoetin beta (Hb level 11‐12.5 g/dl, target Hb 13‐15 g/dl)
Study: 11369844
Drug: Late intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late intervention with epoetin beta (Hb level <10.5 g/dl, target Hb 10.5‐11.5 g/dl)
Study: 9416886
Drug: Sitostanol ester
Normalized name: disodium ascorbyl sitostanol phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitostanol ester margarine (3 g/d) for 7 weeks
Study: 8512911
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) applied to one side of the mouth after surgery
Study: 2979215
Drug: Intravenous famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous famotidine at 10 ng ml-1
Study: 2979215
Drug: Intravenous famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous famotidine at 30 ng ml-1
Study: 2979215
Drug: Intravenous famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous famotidine at 90 ng ml-1
Study: 29565636
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care + Homeopathy Treatment (UC + HT)
Study: 26693800
Drug: DHAP (dexamethasone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHAP (dexamethasone, high-dose cytarabine, cisplatin)
Study: 24527578
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine treatment
Study: 24527578
Drug: Regular Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular Western and Chinese medicine treatments
Study: 11982446
Drug: Citalopram medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram medication
Study: 11982446
Drug: Both treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both treated groups (Citalopram and Cognitive-behavioral therapy)
Study: 11982446
Drug: Responders (regardless
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders (regardless of treatment approach)
Study: 8552510
Drug: Intravenous aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous aspirin (0.015 g/kg body weight)
Study: 21779973
Drug: Psyllium (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (3.6 g × 2/day) during rehabilitation
Study: 21779973
Drug: High-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber diet (approximately 30 g fiber per day) during rehabilitation
Study: 9758264
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.8 mg)‐containing multivitamin supplementation
Study: 9758264
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (1 mg)‐containing multivitamin
Study: 9758264
Drug: Physiological dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological dose (<1 mg) of folic acid
Study: 4359162
Drug: l(‐) amphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: l(‐) amphetamine
Study: 4359162
Drug: l(‐) amphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: l(‐) amphetamine and d(+) amphetamine
Study: 31943197
Drug: Amitriptyline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (10 to 50 mg daily)
Study: 24040767
Drug: Retransfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retransfusion of unwashed cardiotomy suction blood (mean volume 280 ml, corresponding to 5% of blood volume)
Study: 19522261
Drug: Perioperative epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative epidural buprenorphine 0.2 mg
Study: 11765143
Drug: Capsule formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulation (500 mg sitafloxacin)
Study: 11765143
Drug: Intravenous formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous formulation (400 mg sitafloxacin)
Study: 9267668
Drug: Paclitaxel 170
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 170 mg/m2 and Cyclophosphamide 2 gm/m2
Study: 9267668
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 and Cyclophosphamide 3 gm/m2
Study: 9267668
Drug: Prior chemotherapy
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior chemotherapy regimen (1 vs more than 1)
Study: 9267668
Drug: Prior radiation
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior radiation therapy
Study: 8488991
Drug: etomidate in
Normalized name: etomidate Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: etomidate in lipid emulsion formulation (Lipofundin MCT 20%; eto-lip)
Study: 3449066
Drug: Ambroxol, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol, 3 x 30 mg for 7 days
Study: 3449066
Drug: Gelomyrtol forte,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelomyrtol forte, 4 x 1 capsule (1 capsule = 0.3 g Myrtol, standardized to at least 20 mg of alpha-pinene, 75 mg of limonene, and 75 mg of cineole) for 7 days
Study: 29475197
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy regimens
Study: 23134522
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 30 mg plus valsartan 80 mg (N + V)
Study: 23134522
Drug: High-dose valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose valsartan (160 mg) monotherapy (V160)
Study: 19026302
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg plus ezetimibe 10 mg
Study: 15808114
Drug: SIT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT with modified Dermatophagoides pteronyssinus 100 % allergen vaccine (n = 25)
Study: 15808114
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pharmacological treatment only, n = 25)
Study: 14506330
Drug: Rebamipide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (100 mg, 3 times/day for 7 days before surgery)
Study: 9607389
Drug: Fosinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (10 to 20 mg daily orally)
Study: 9607389
Drug: Atenolol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (25 to 50 mg daily orally)
Study: 2650581
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg daily
Study: 2650581
Drug: Quinapril 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 80 mg daily
Study: 22809664
Drug: Paracetamol (60/80/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (60/80/100 mg based on birth weight)
Study: 21336727
Drug: VitalStim therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VitalStim therapy plus conventional swallowing training
Study: 21336727
Drug: VitalStim therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VitalStim therapy
Study: 10654038
Drug: OGA L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OGA L film using Lanex Regular screens (Lanex group)
Study: 9299800
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy alone
Study: 9299800
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluoxetine and cognitive behavior therapy
Study: 8345004
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 3000 mg
Study: 8345004
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 2000 mg
Study: 8345004
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 1000 mg
Study: 8345004
Drug: Total drug
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total drug concentration above 100 mg/l